>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Anti-BCMA Neutralizing Antibody, Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) with a linear range of 0.256-6.4 ng/mL (QC tested).
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) and 0.01 μg/mL (100 μL/well) Biotinylated Human BAFF, His,Avitag (Cat. No. BAF-H82Q2) with a half maximal inhibitory concentration (IC50) of 4.877 μg/mL (Routinely tested).
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) and 0.05 μg/mL (100 μL/well) Biotinylated Human APRIL, Fc,Avitag (Cat. No. APL-H82F5) with a half maximal inhibitory concentration (IC50) of 4.624 μg/mL (Routinely tested).
Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.
A-Z
